Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital
February 11, 2022 7:21 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.
The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More
